Sucampo receive Japanese acceptance for AMITIZA Sucampo Pharmaceuticals.

Related StoriesScripps Florida scientists win $2.4 million to expand development of new pain therapies ‘We are very very happy to receive Japan’s first-ever acceptance for a prescription drugs for chronic constipation since it helps us achieve our objective of getting medicines with novel mechanisms of action to patients with unmet medical needs on a worldwide basis,’ said Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo’s Chairman and Chief Executive Officer. ‘We look forward to working with Abbott to meet the needs of these patients in Japan.’ In 2009 2009, Sucampo and Abbott Japan Co.Income level also played a job, the findings suggested. Our study indicated that moms with low income were significantly less more likely to breast-feed or to have taken the youngster to the dental practitioner in the last year. They were less inclined to feed their child breakfast than higher-income counterparts also, said Sabbah. It is important to better understand the dynamics of the links, so that we would develop effective public wellness programs and interventions. It’s known that poverty is associated with chronic exposure to adverse living circumstances, added the study’s initial author, Erin Masterson, from the Institutions of Public Health insurance and Dentistry at the University of Washington in Seattle.